Hair Loss News and Research

RSS

Scars, disfigurement and hair loss from childhood cancer can affect adult quality of life

Scars left behind by childhood cancer treatments are more than skin-deep. The increased risk of disfigurement and persistent hair loss caused by childhood cancer and treatment are associated with emotional distress and reduced quality of life in adulthood, according to a new study led by a Northwestern Medicine advanced practice nurse, Karen Kinahan, and based on data from the Childhood Cancer Survivor Study.

25 May 2012

New strategy can reactivate genes that cause cancer tumors to shrink and die

A team of scientists has developed a promising new strategy for "reactivating" genes that cause cancer tumors to shrink and die. The researchers hope that their discovery will aid in the development of an innovative anti-cancer drug that effectively targets unhealthy, cancerous tissue without damaging healthy, non-cancerous tissue and vital organs.

22 May 2012

Apigenin effective against human breast cancer

Apigenin, a natural substance found in grocery store produce aisles, shows promise as a non-toxic treatment for an aggressive form of human breast cancer, following a new study at the University of Missouri.

17 May 2012

Non-toxic green tea shampoo to treat dandruff

Dandruff sufferers now have a non-toxic product to treat the condition, says a researcher at Georgia Health Sciences University.

2 May 2012

Scientists grow hair on bald mice

Japanese researchers have successfully regrown hair on a bald mouse. This could mean hair related solutions for many men and women with baldness in future.

22 Apr 2012

Study pinpoints mechanism by which spindle checkpoint proteins bind chromosomes

The development of more effective cancer drugs could be a step nearer thanks to the discovery, by scientists at Warwick Medical School, of how an inbuilt 'security check' operates to guarantee cells divide with the correct number of chromosomes.

21 Apr 2012

UTHealth researcher studies novel cell therapy to prevent GVHD

A researcher at The University of Texas Health Science Center at Houston (UTHealth) is studying a novel cell therapy that could help avoid autoimmune problems after stem cell transplantation, as well as potentially treat other autoimmune diseases.

17 Apr 2012

UC professor to show new anticancer agent at ACS Spring 2012 meeting

Advances in chemotherapy have dramatically improved the outlook for many cancer patients, but the side effects of this treatment are daunting. A new generation of chemotherapy drugs with fewer side effects is the goal of Edward J. Merino, assistant professor of chemistry at the University of Cincinnati.

27 Mar 2012

Male pattern baldness causes discovered

Most men start to go bald in middle age, with about 80% of men having some hair loss by the age of 70. Male pattern baldness is the most common type of hair loss for men, the National Institute of Health said. Symptoms include a thinning of hair at the hairline, eventually creating a U-shaped or horseshoe pattern of hair on both sides of the head. The male sex hormone testosterone plays a key role, as do genetic factors. They cause the hair follicles to shrink, eventually becoming so small that they are invisible, leading to the appearance of baldness. While treatment is not necessary, side effects including psychological stress and loss of self-esteem due to change in appearance can be experienced.

25 Mar 2012

Issues and treatments of chronic skin wounds

The skin is the body's largest organ and an indispensable part of the immune system. As the body's outermost line of defense against microbes, the skin provides important protection against potentially toxic environmental elements. One subset of immune cells, thymus-derived T-cells play an important role in the skin's response to injury, particularly with respect to wound healing.

21 Mar 2012

Styling practices linked with hair or scalp diseases among African Americans

Styling practices can lead to serious hair and scalp diseases for some African Americans, says Henry Ford Hospital dermatologist Diane Jackson-Richards, M.D.

20 Mar 2012

Vitamin A daily dose may help prevent skin cancer: Study

A study has shown that a daily vitamin pill could help prevent skin cancer - particularly among women. Scientists say taking food supplements containing vitamin A can make people less likely to develop melanoma, the deadliest form of the disease.

4 Mar 2012

Restoration Robotics ARTAS hair transplantation system receives Canadian Medical Device License

Restoration Robotics, Inc., a privately-held medical device company, today announced that its revolutionary ARTAS System has received a Canadian Medical Device License and can now be marketed and sold within Canada.

27 Feb 2012

Skin cancer drug may prolong survival in advanced cases: Study

Researchers say 132 patients in the U.S. and Australia who were given the drug vemurafenib gained several extra months of life. The study published in the New England Journal of Medicine found that those on the drug lived an average of 16 months, compared with nine months on conventional treatment.

26 Feb 2012

Vemurafenib nearly doubles survival for patients with metastatic melanoma

Investigators from Vanderbilt-Ingram Cancer Center (VICC) and 12 other centers in the United States and Australia have found that a new drug for patients with metastatic melanoma nearly doubled median overall survival.

23 Feb 2012

New triple-therapies found cost-effective for chronic hepatitis C patients with advanced liver disease

A towering $60,000 bill, a year of fierce, flu-like symptoms and a running risk of depression are among the possible costs of two new hepatitis C treatments. But according to Stanford University health policy researchers, they might be worth it.

21 Feb 2012

EC approves Plexxikon's Zelboraf to treat BRAF mutation-positive MM

Plexxikon Inc., a member of Daiichi Sankyo Group, today announced that the European Commission has approved Zelboraf (vemurafenib) for the monotherapy treatment of adult patients with BRAFV600 mutation-positive unresectable or metastatic melanoma.

20 Feb 2012

Roche’s skin cancer drug Erivedge gets FDA nod

The Food and Drugs Administration (FDA) this Monday approved a pill that treats the most common type of skin cancer, basal cell carcinoma.

31 Jan 2012

FDA approves Genentech's Erivedge for treatment of BCC

Genentech, a member of the Roche Group, today announced that Erivedge (vismodegib) capsule was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with a type of skin cancer, called basal cell carcinoma (BCC), that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation.

31 Jan 2012

Genentech receives FDA approval for Erivedge to treat basal cell carcinoma

Today, Erivedge (vismodegib) was approved by the U.S. Food and Drug Administration to treat adult patients with basal cell carcinoma, the most common type of skin cancer. The drug is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body.

31 Jan 2012